UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 32-0463781 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) (State or other jurisdiction of incorporation or organization) (I.R.S. employer identification number) 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091 (Address of principal executive offices) (zip code) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2022 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2021 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _______________ to ________________ Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) DELAWARE 32-046 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Delaware 32-0463781 (I.R.S. employer For the transition period from to identification number) Commission File Number: 001-39070 (Mark One) MONOPAR THERAPEUTICS INC. ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended June 30, 2021 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) Delaware 32-0463781 (State or other jurisdic ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2021 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) DELAWARE 32-0463781 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Fiscal Year Ended December 31, 2020 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from _______________ to ________________ Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) DELAWARE 32-046 ...

财务数据关键指标变化：研发费用 - 2020年第三季度研发费用为125.6万美元，较2019年同期的22万美元增长103.6万美元，增幅约471%[144][145] - 2020年前九个月研发费用为243.3万美元，较2019年同期的138.5万美元增长104.8万美元，增幅约76%[144][146] 财务数据关键指标变化：总运营费用和净亏损 - 2020年第三季度总运营费用为164.8万美元，较2019年同期的75.9万美元增长88.9万美元，增幅约117%[144] - 2020年前九个月总运营费用为424.8万美元，较2019年同期的309.9万美元增长114.9万美元，增幅约37%[144] - 2020年第三季度净亏损为163.9万美元，较2019年同期的73.6万美元增加90.3万美元[144] - 2020年前九个月净亏损为301.8万美元，而2019年同期数据不明确[144] 财务数据关键指标变化：现金流 - 2020年前九个月经营活动所用现金净额为342.1万美元，较2019年同期的234.9万美元增加107.2万美元[156][157] - 2020年前九个月融资活动提供现金净额为818.9万美元，而2019年同期为使用现金净额3.9万美元，增加822.8万美元[156][159] 业务线表现：Validive (口咽癌) - 在已完成的口咽癌患者二期临床试验中，与安慰剂组相比，每日一次100 µg剂量Validive将严重口腔黏膜炎的绝对发生率降低了26.3%[129] - 在二期临床试验中，Validive 100 µg组患者严重口腔黏膜炎的中位持续时间比安慰剂组减少37.8%（25.5天对比41.0天）[129] - 2020年美国口咽癌新病例估计超过40,000例，是头颈癌患者中增长最快的群体[131] - 公司预计Validive的全球知识产权专利保护将持续到2029年中期[128] 业务线表现：Camsirubicin (软组织肉瘤) - 针对晚期软组织肉瘤患者的二期临床试验显示，52.6%可评估肿瘤进展的患者从camsirubicin中获得临床获益[133] - camsirubicin在临床研究中显示出良好耐受性，可能不受累积剂量限制，而多柔比星的终身累积剂量上限为450 mg/m²[133] - 公司计划与GEIS合作进行一项约170名晚期软组织肉瘤患者的多国随机二期临床试验[134] 管理层讨论和指引：资金需求与财务状况 - 公司预计为完成Validive的三期临床试验部分，需要数百万至数千万美元的额外资金[126] - 公司截至2020年9月30日的累计赤字约为3010万美元[152] - 截至2020年10月31日的可用资金预计可支持公司运营至2021年12月[152][163] - Validive的III期临床试验启动需要额外融资数百万至数千万美元（取决于是否达成合作）[165] - 公司预计在未来12个月内需要筹集额外资金以启动Validive的III期试验部分[165] - 公司计划通过股权发行、债务融资、战略合作和赠款资金等方式满足未来现金需求[166] 管理层讨论和指引：未来运营成本 - 公司预计2020年第四季度及以后的运营成本将增加，主要受Validive IIb/III期和camsirubicin II期试验资助驱动[165] - 与GEIS合作的camsirubicin II期临床试验每年平均支持费用约为200万至300万美元[170] 融资活动 - 公司首次公开募股以每股8.00美元的价格出售1,277,778股普通股，净收益约940万美元[121] - 根据资本需求销售协议，公司以每股平均毛价格9.79美元出售860,677股普通股，净收益为8,175,290美元[122] 合作协议与相关费用 - 与Onxeo的Validive许可协议包含最高可达1.08亿美元的里程碑付款，以及5%至10%的阶梯式销售分成[167] - 与XOMA的MNPR-101许可协议包含最高可达1,492.5万美元的临床、监管和销售里程碑付款[172] - 截至2020年9月30日的三个月和九个月，公司发生与GEIS及其他临床相关的费用分别为400,320美元和612,304美元[170] 其他重要内容 - 公司总部办公室月租金为2,520美元，租约到期后转为按月租赁[174]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) | DELAWARE | 32-0463781 | | --- | --- | | (State or other jurisdiction of incorporation or organization) | (I.R.S. employer | | | identification number) | | 1000 Skokie Blvd., Suite 350, Wilmette, IL | 60091 | | (Address of principal executive offices) | (zip code) | | (847) 388-0349 | | | (Registrant's telephone number, including area ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Quarterly Period Ended March 31, 2020 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 001-39070 MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter) | DELAWARE | | 32-0463781 | | --- | --- | - ...